CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Erasca Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Erasca Inc
10835 Road To The Cure, Suite 140
Phone: (858) 465-6511p:858 465-6511 SAN DIEGO, CA  92121-1130  United States Ticker: ERASERAS

Business Summary
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline including 12 disclosed modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. The Company’s pipeline includes five clinical-stage programs, such as a pan-RAF inhibitor, an ERK inhibitor, a SHP2 inhibitor, an EGFR inhibitor, and a central nervous system (CNS)-penetrant KRAS G12C inhibitor, and seven discovery-stage programs targeting other key oncogenic drivers. The Company’s lead product candidate is naporafenib, designed to be a reversible, potent and selective ATP-competitive type 2 pan-RAF kinase inhibitor.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202312/31/2022YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer, Co-Founder Jonathan E.Lim 51 7/1/2018 7/1/2018
Chief Financial Officer and Chief Business Officer David M.Chacko 40 5/15/2023 1/1/2019
Director, Chair of Research and Development Michael D.Varney 65 12/1/2020 8/1/2020
9 additional Officers and Directors records available in full report.

Business Names
Business Name
ERAS
ERASCA INCORPORATED

General Information
Number of Employees: 129 (As of 2/28/2023)
Outstanding Shares: 151,087,038 (As of 11/2/2023)
Shareholders: 53
Stock Exchange: NASD
Federal Tax Id: 831217027
Fax Number: (302) 636-5454
Email Address: info@erasca.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024